Form 4: Zimmer Biomet Director Syed Jafry Acquires Phantom Stock
Director Equity Disclosure
Director Syed A. Jafry acquired 182.421 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan.
Summary
- Director Syed A. Jafry acquired 182.421 phantom stock units on March 31, 2026.
- The units were acquired under the company's Deferred Compensation Plan for Non-Employee Directors.
- The conversion price for these units is 1-for-1.
- The total beneficial ownership following this transaction is 7,391.591 phantom stock units.
- These units are settled in shares of common stock within 60 days after the director ceases service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices with no impact on company operations or financial strategy.
Positives
- Demonstrates continued alignment of director interests with shareholders through participation in the deferred compensation plan.
Future Outlook
The units are scheduled to be settled in common stock upon the cessation of the director's service to the company.
Management Comments
- The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation and equity alignment, common among large-cap medical device companies to ensure board members maintain a long-term stake in company performance.
Comparison to Industry Standards
- The use of deferred compensation plans for non-employee directors is a standard corporate governance practice among S&P 500 companies.
- The 1-for-1 conversion ratio is consistent with standard equity-based compensation structures for board members.
Stakeholder Impact
- Minimal impact on shareholders as this represents standard director compensation.
Next Steps
- Settlement of units into common stock upon the director's eventual departure from the board.
Key Dates
| Date | Description |
|---|---|
| 07/31/2025 | Accrual of 18.122 phantom stock units via dividend reinvestment. |
| 10/31/2025 | Accrual of 17.223 phantom stock units via dividend reinvestment. |
| 01/30/2026 | Accrual of 20.035 phantom stock units via dividend reinvestment. |
| 03/31/2026 | Transaction date for the acquisition of 182.421 phantom stock units. |
| 04/02/2026 | Filing date of the Form 4. |
Keywords
Zimmer Biomet, ZBH, Form 4, Insider Trading, Director Compensation, Phantom Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.